Announced
Completed
Synopsis
RA Capital Management and Nextech Invest led a $105m Series B round in Boundless Bio, a next-generation precision oncology company, with participation from Fidelity Management & Research Company, Redmile Group, Wellington Management, Surveyor Capital, PFM Health Sciences, Logos Capital, ARCH Venture Partners, City Hill Ventures, Vertex Ventures HC, GT Healthcare Capital Partners, Boxer Capital and Alexandria Venture Investments. "RA Capital has been following the Boundless Bio story for some time now and believes that the team has developed industry-leading expertise in the biology that underlies high unmet need, gene amplified tumors," Zach Scheiner, RA Capital Management Principal.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.